Form 4: Alector Officer Sells Shares Under 10b5-1 Plan

Alector's Principal Accounting Officer, Grace Wong-Sarad, sold 4,079 shares of common stock for $2.50 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Grace Wong-Sarad, Principal Accounting Officer of Alector, Inc. (ALEC), reported a sale of common stock.
• On February 26, 2026, 4,079 shares of Alector common stock were disposed of.
• The transaction occurred at a price of $2.50 per share.
• Following this transaction, Grace Wong-Sarad directly owns 118,903 shares of Alector common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan established on September 5, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine insider transaction executed under a pre-arranged 10b5-1 plan, which typically does not signal a change in company fundamentals or management's outlook.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common in the biotechnology sector as executives manage personal portfolios and liquidity. The use of a 10b5-1 plan is a standard practice to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• Insider sales executed under Rule 10b5-1 plans are a common and accepted practice across all industries, including biotechnology, for executives to manage personal equity holdings in a compliant manner. This transaction aligns with standard corporate governance practices for insider trading.

Stakeholder Impact

• Shareholders: The sale represents a minor disposition of shares by an officer, which is unlikely to have a significant impact on the company's overall share structure or valuation. The pre-planned nature of the sale mitigates potential negative sentiment often associated with insider selling.

Key Dates

Recommendation

The filing reports a routine insider stock sale executed under a pre-established 10b5-1 trading plan. This type of transaction is generally considered neutral and does not provide new information that would warrant a change in investment recommendation. The sale is a small percentage of the officer's total holdings and is part of a pre-planned liquidity management strategy, not an indication of a change in company fundamentals. Therefore, a 'hold' recommendation is appropriate as the filing does not present new catalysts for buying or selling.

Keywords

Alector, ALEC, Insider Trading, Form 4, Stock Sale, Grace Wong-Sarad, 10b5-1 Plan, Officer Transaction, Biotechnology